347 related articles for article (PubMed ID: 32603772)
21. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
Moutsopoulos HM
Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
[No Abstract] [Full Text] [Related]
22. Immunomodulation in COVID-19.
Ingraham NE; Lotfi-Emran S; Thielen BK; Techar K; Morris RS; Holtan SG; Dudley RA; Tignanelli CJ
Lancet Respir Med; 2020 Jun; 8(6):544-546. PubMed ID: 32380023
[No Abstract] [Full Text] [Related]
23. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
El-Missiry MA; El-Missiry ZMA; Othman AI
Eur J Pharmacol; 2020 Sep; 882():173329. PubMed ID: 32615182
[TBL] [Abstract][Full Text] [Related]
24. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.
McCarty MF; DiNicolantonio JJ
Prog Cardiovasc Dis; 2020; 63(3):383-385. PubMed ID: 32061635
[No Abstract] [Full Text] [Related]
25. COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause.
Fernandez-Gutierrez B
Reumatol Clin (Engl Ed); 2020; 16(4):253-254. PubMed ID: 32345483
[No Abstract] [Full Text] [Related]
26. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
27. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
28. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
Paniri A; Akhavan-Niaki H
Life Sci; 2020 Sep; 257():118114. PubMed ID: 32693241
[TBL] [Abstract][Full Text] [Related]
29. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
30. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
Feldmann M; Maini RN; Woody JN; Holgate ST; Winter G; Rowland M; Richards D; Hussell T
Lancet; 2020 May; 395(10234):1407-1409. PubMed ID: 32278362
[No Abstract] [Full Text] [Related]
31. Covid-19 management with inflammation resolving mediators? Perspectives and potential.
Regidor PA
Med Hypotheses; 2020 Sep; 142():109813. PubMed ID: 32416413
[No Abstract] [Full Text] [Related]
32. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
Ascierto PA; Fox BA; Urba WJ; Anderson AC; Atkins MB; Borden EC; Brahmer JR; Butterfield LH; Cesano A; Chen DC; de Gruijl TD; Dillman RO; Drake CG; Emens LA; Gajewski TF; Gulley JL; Stephen Hodi FJ; Hwu P; Kaufman D; Kaufman HL; Lotze MT; McNeel DG; Margolin KM; Marincola FM; Mastrangelo MJ; Maus MV; Parkinson DR; Romero PJ; Sondel PM; Spranger S; Sznol M; Weiner GJ; Wigginton JM; Weber JS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32300051
[No Abstract] [Full Text] [Related]
33. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients.
Liao S; Zhan K; Gan L; Bai Y; Li J; Yuan G; Cai Y; Zhang A; He S; Mei Z
Signal Transduct Target Ther; 2020 Oct; 5(1):255. PubMed ID: 33130825
[No Abstract] [Full Text] [Related]
35. The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19.
Huang YX; Wang WX; Zhang S; Tang YP; Yue SJ
Pharmacol Res; 2020 Sep; 159():105046. PubMed ID: 32590099
[No Abstract] [Full Text] [Related]
36. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
Deftereos S; Giannopoulos G; Vrachatis DA; Siasos G; Giotaki SG; Cleman M; Dangas G; Stefanadis C
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):255. PubMed ID: 32337546
[No Abstract] [Full Text] [Related]
37. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
Front Immunol; 2020; 11():1708. PubMed ID: 32754163
[TBL] [Abstract][Full Text] [Related]
38. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
Schumann S; Kaiser A; Nicoletti F; Mangano K; Fagone P; van Wijk E; Yan Y; Schulz P; Ludescher B; Niedermaier M; von Wegerer J; Rauch P; Setz C; Schubert U; Brysch W
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233817
[TBL] [Abstract][Full Text] [Related]
39. Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J
Shahzad S; Willcox M
Med Hypotheses; 2020 Oct; 143():110080. PubMed ID: 32683221
[TBL] [Abstract][Full Text] [Related]
40. Statin therapy and SAR-COV-2: an available and potential therapy?
Abdel-Latif RG; Mohammed S; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
